Unity Biotechnology 将来の成長

Future 基準チェック /36

Unity Biotechnology利益と収益がそれぞれ年間55.2%と68.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-61.2% 54.3%なると予測されています。

主要情報

55.2%

収益成長率

54.3%

EPS成長率

Biotechs 収益成長	43.0%
収益成長率	68.3%
将来の株主資本利益率	-61.2%
アナリストカバレッジ	Low
最終更新日	15 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:9U9 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	26	-13	N/A	N/A	2
12/31/2025	N/A	-32	N/A	N/A	2
12/31/2024	N/A	-25	N/A	N/A	2
9/30/2024	N/A	-22	-23	-23	N/A
6/30/2024	N/A	-30	-24	-24	N/A
3/31/2024	N/A	-40	-31	-31	N/A
12/31/2023	N/A	-40	-37	-37	N/A
9/30/2023	N/A	-34	-41	-41	N/A
6/30/2023	N/A	-33	-45	-45	N/A
3/31/2023	0	-31	-49	-49	N/A
12/31/2022	0	-44	-53	-52	N/A
9/30/2022	5	-56	-46	-46	N/A
6/30/2022	5	-59	-47	-46	N/A
3/31/2022	5	-64	-45	-45	N/A
12/31/2021	5	-61	-45	-45	N/A
9/30/2021	N/A	-70	-57	-57	N/A
6/30/2021	N/A	-81	-63	-62	N/A
3/31/2021	N/A	-82	-69	-68	N/A
12/31/2020	N/A	-94	-79	-78	N/A
9/30/2020	N/A	-92	-78	-77	N/A
6/30/2020	N/A	-86	-78	-77	N/A
3/31/2020	N/A	-91	-78	-77	N/A
12/31/2019	N/A	-82	-74	-72	N/A
9/30/2019	N/A	-86	-71	-70	N/A
6/30/2019	N/A	-83	-68	-67	N/A
3/31/2019	N/A	-79	-67	-65	N/A
12/31/2018	N/A	-76	-58	-57	N/A
9/30/2018	1	-67	-57	-55	N/A
6/30/2018	1	-60	N/A	-51	N/A
3/31/2018	1	-52	N/A	-42	N/A
12/31/2017	1	-45	N/A	-38	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 9U9は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: 9U9今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 9U9今後 3 年以内に収益を上げることが予想されます。

収益対市場: 9U9来年は収益がないと予測されています。

高い収益成長: 9U9来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 9U9 3 年以内に赤字になると予測されています。

Unity Biotechnology 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

New minor risk - Share price stability

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

New major risk - Financial position

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: €6.20

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: €5.29

Unity Biotechnology Announces Executive Changes

New 90-day high: €4.03

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - €2.48

New 90-day high - €10.22

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘